Hypoglycaemia, whilst less common with GLP-1 receptor agonists used alone, can occur when Ozempic is combined with other glucose-lowering medications such as sulphonylureas or insulin
Maffioletti, E., Zanardini, R., Gennarelli, M
Long-Term Tolerance Still Matters Side effects should not be dismissed simply because treatment has continued for several months
The full list of exclusion criteria is available in the Supplementary material
Sources KFF health tracking poll May 2024: The publics use and views of GLP-1 drugs GLP-1 global forecast JP Morgan obesity drugs research Novo Nordisk market trends US weight loss drug prices vs other countries MIT report on GLP-1s Fortune Magazine report on Ozempic and Wegovy Yahoo Finance Novo Nordisk A/S (NVO) CNBC soaring demand for Wegovy and Ozempic FAIR Health white paper on obesity and GLP-1 drugs JAMA research letter on risk of gastrointestinal adverse events with GLP-1 drugs University of Queenslands risks and benefits of Ozempic Business model reinvention GLP-1 trends & impact survey
SUFFERED GASTROPARESIS OR STOMACH PARALYSIS
